Skip to main content
Equibles
AMLX logo

AMLX · Amylyx Pharmaceuticals, Inc. · Metrics

Track AMLX — free

Use AMLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$29.50 +0.73 (+2.54%)
Russell 2000 member Rebalance outlook locked
Market Cap
$3.28B
Shares
111.42M
Volume · Oct 21 741.55K Avg daily vol (3M) 2.32M

AMLX metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$28.77
Market cap
$3.28B

Price action

20 metrics
Price change (1W)
+7.2%
Price change (30D)
-11.2%
Price change (3M)
+55.5%
Price change (6M)
+63.6%
Price change (YTD)
+138.2%
Price change (1Y)
+87.2%
Trailing year
Price change (5Y)
—
52-week high
$39.66
52-week low
$11.38
Change from 52-week high
-27.5%
Change from 52-week low
+152.8%
Annualized volatility
86.6%
Annualized volatility (3M)
138.6%
Beta
0.9
RSI (14D)
50.0
Price vs SMA 50
-6.9%
Price vs SMA 200
+48.0%
Avg volume (3M)
2.32M
Relative volume
0.7
Average dollar volume
$70.85M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
111.42M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
13.4
reciprocal yield 7.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.8×
reciprocal yield 124.7%
EV / revenue historical average (5Y)
0.8×
reciprocal yield 124.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-18

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$162.10M
Net income (TTM)
−$152.09M
Trailing 12 months
Diluted EPS (TTM)
$-1.41
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$-0.01
Gross profit per diluted share (TTM)
$-0.01
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.78

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+24.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-63.6%
Return on assets
-57.5%
Debt / equity
0.0
Current ratio
12.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$250.76M
Latest balance sheet
Cash & equivalents
$49.33M
Total assets
$264.56M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$126.58M
Capital expenditures (TTM)
$140,000
R&D (TTM)
$92.45M
SG&A (TTM)
$69.66M
Stock compensation (TTM)
$27.90M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
207
13F filer change QoQ
+34
Institutional ownership
103.8%
Conviction holders (share of 13F filers)
2.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-2.2%
Holder tenure
9.0
Price vs estimated holder cost
+84.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.7%

Short interest

3 metrics
Short interest
11.4%
Latest settlement · 9.2 days to cover
Days to cover
9.2d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.78M
Insider-sentiment score
14 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1658551 CUSIP 03237H101 13F (30d) 15 filings 15 filers Visit website Investor relations